Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

H3 Pharma Plans First Quarter Response To Sanvar IR "Approvable" Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA letter requests additional supportive efficacy data and further information related to manufacturing. H3 Pharma expects that the results from a recently completed Phase III study will address the issues cited in the letter.
Advertisement

Related Content

Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
Good Trials Built On Sturdy Protocols, Not Just SPA Agreements With FDA
Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar
Debiopharm Takes Up Confirmatory Phase III Trial Of Sanvar

Topics

Advertisement
UsernamePublicRestriction

Register

PS061020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel